Blockade of CD26 signaling inhibits human osteoclast development

Hiroko Nishida, Hiroshi Suzuki, Hiroko Madokoro, Mutsumi Hayashi, Chikao Morimoto, Michiie Sakamoto, Taketo Yamada

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Bone remodeling is maintained by the delicate balance between osteoblasts (OBs) and osteoclasts (OCs). However, the role of CD26 in regulating bone remodeling has not yet been characterized. We herein show that CD26 is preferentially expressed on normal human OCs and is intensely expressed on activated human OCs in osteolytic bone alterations. Macrophage-colony stimulating factor (M-CSF) and soluble receptor activator of NF-kB ligand (sRANKL) induced human OC differentiation, in association with CD26 expression on monocyte-macrophage lineage cells. CD26 expression was accompanied by increased phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK), which is crucial for early human OC differentiation. The humanized anti-CD26 monoclonal antibody, huCD26mAb, impaired the formation and function of tartrate-resistant acid phosphatase (TRAP)/CD26 positive multi-nucleated (nuclei>3) OCs with maturation in the manner of dose-dependency. It was revealed that huCD26mAb inhibits early OC differentiation via the inactivation of MKK3/6, p38 MAPK and subsequent dephosphorylation of microphthalmia-associated transcription factor (mi/Mitf). These inhibitions occur immediately after RANKL binds to RANK on the human OC precursor cells and were demonstrated using the OC functional assays. huCD26mAb subsequently impaired OC maturation and bone resorption by suppressing the expression of TRAP and OC fusion proteins. In addition, p38 MAPK inhibitor also strongly inhibited OC formation and function. Our results suggest that the blockade of CD26 signaling impairs the development of human functional OCs by inhibiting p38 MAPK-mi/Mitf phosphorylation pathway and that targeting human OCs with huCD26mAb may have therapeutic potential for the treatment of osteolytic lesions following metastasis to alleviate bone destruction and reduce total skeletal-related events (SREs).

Original languageEnglish
Pages (from-to)2439-2455
Number of pages17
JournalJournal of Bone and Mineral Research
Volume29
Issue numberS1
DOIs
Publication statusPublished - 2014 Feb 1

Fingerprint

Human Development
Osteoclasts
p38 Mitogen-Activated Protein Kinases
Microphthalmia-Associated Transcription Factor
Bone Remodeling
Macrophage Colony-Stimulating Factor Receptors
Phosphorylation
Bone and Bones
NF-kappa B
Protein Kinase Inhibitors
Bone Resorption
Osteoblasts
Monocytes

Keywords

  • Bone resorption
  • CD26
  • Osteoclast
  • Osteoclast precursor
  • P38 mapk

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Nishida, H., Suzuki, H., Madokoro, H., Hayashi, M., Morimoto, C., Sakamoto, M., & Yamada, T. (2014). Blockade of CD26 signaling inhibits human osteoclast development. Journal of Bone and Mineral Research, 29(S1), 2439-2455. https://doi.org/10.1002/jbmr.2277

Blockade of CD26 signaling inhibits human osteoclast development. / Nishida, Hiroko; Suzuki, Hiroshi; Madokoro, Hiroko; Hayashi, Mutsumi; Morimoto, Chikao; Sakamoto, Michiie; Yamada, Taketo.

In: Journal of Bone and Mineral Research, Vol. 29, No. S1, 01.02.2014, p. 2439-2455.

Research output: Contribution to journalArticle

Nishida, H, Suzuki, H, Madokoro, H, Hayashi, M, Morimoto, C, Sakamoto, M & Yamada, T 2014, 'Blockade of CD26 signaling inhibits human osteoclast development', Journal of Bone and Mineral Research, vol. 29, no. S1, pp. 2439-2455. https://doi.org/10.1002/jbmr.2277
Nishida, Hiroko ; Suzuki, Hiroshi ; Madokoro, Hiroko ; Hayashi, Mutsumi ; Morimoto, Chikao ; Sakamoto, Michiie ; Yamada, Taketo. / Blockade of CD26 signaling inhibits human osteoclast development. In: Journal of Bone and Mineral Research. 2014 ; Vol. 29, No. S1. pp. 2439-2455.
@article{eeeca53f1dc442f183e1c5fd888a3a0c,
title = "Blockade of CD26 signaling inhibits human osteoclast development",
abstract = "Bone remodeling is maintained by the delicate balance between osteoblasts (OBs) and osteoclasts (OCs). However, the role of CD26 in regulating bone remodeling has not yet been characterized. We herein show that CD26 is preferentially expressed on normal human OCs and is intensely expressed on activated human OCs in osteolytic bone alterations. Macrophage-colony stimulating factor (M-CSF) and soluble receptor activator of NF-kB ligand (sRANKL) induced human OC differentiation, in association with CD26 expression on monocyte-macrophage lineage cells. CD26 expression was accompanied by increased phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK), which is crucial for early human OC differentiation. The humanized anti-CD26 monoclonal antibody, huCD26mAb, impaired the formation and function of tartrate-resistant acid phosphatase (TRAP)/CD26 positive multi-nucleated (nuclei>3) OCs with maturation in the manner of dose-dependency. It was revealed that huCD26mAb inhibits early OC differentiation via the inactivation of MKK3/6, p38 MAPK and subsequent dephosphorylation of microphthalmia-associated transcription factor (mi/Mitf). These inhibitions occur immediately after RANKL binds to RANK on the human OC precursor cells and were demonstrated using the OC functional assays. huCD26mAb subsequently impaired OC maturation and bone resorption by suppressing the expression of TRAP and OC fusion proteins. In addition, p38 MAPK inhibitor also strongly inhibited OC formation and function. Our results suggest that the blockade of CD26 signaling impairs the development of human functional OCs by inhibiting p38 MAPK-mi/Mitf phosphorylation pathway and that targeting human OCs with huCD26mAb may have therapeutic potential for the treatment of osteolytic lesions following metastasis to alleviate bone destruction and reduce total skeletal-related events (SREs).",
keywords = "Bone resorption, CD26, Osteoclast, Osteoclast precursor, P38 mapk",
author = "Hiroko Nishida and Hiroshi Suzuki and Hiroko Madokoro and Mutsumi Hayashi and Chikao Morimoto and Michiie Sakamoto and Taketo Yamada",
year = "2014",
month = "2",
day = "1",
doi = "10.1002/jbmr.2277",
language = "English",
volume = "29",
pages = "2439--2455",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "S1",

}

TY - JOUR

T1 - Blockade of CD26 signaling inhibits human osteoclast development

AU - Nishida, Hiroko

AU - Suzuki, Hiroshi

AU - Madokoro, Hiroko

AU - Hayashi, Mutsumi

AU - Morimoto, Chikao

AU - Sakamoto, Michiie

AU - Yamada, Taketo

PY - 2014/2/1

Y1 - 2014/2/1

N2 - Bone remodeling is maintained by the delicate balance between osteoblasts (OBs) and osteoclasts (OCs). However, the role of CD26 in regulating bone remodeling has not yet been characterized. We herein show that CD26 is preferentially expressed on normal human OCs and is intensely expressed on activated human OCs in osteolytic bone alterations. Macrophage-colony stimulating factor (M-CSF) and soluble receptor activator of NF-kB ligand (sRANKL) induced human OC differentiation, in association with CD26 expression on monocyte-macrophage lineage cells. CD26 expression was accompanied by increased phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK), which is crucial for early human OC differentiation. The humanized anti-CD26 monoclonal antibody, huCD26mAb, impaired the formation and function of tartrate-resistant acid phosphatase (TRAP)/CD26 positive multi-nucleated (nuclei>3) OCs with maturation in the manner of dose-dependency. It was revealed that huCD26mAb inhibits early OC differentiation via the inactivation of MKK3/6, p38 MAPK and subsequent dephosphorylation of microphthalmia-associated transcription factor (mi/Mitf). These inhibitions occur immediately after RANKL binds to RANK on the human OC precursor cells and were demonstrated using the OC functional assays. huCD26mAb subsequently impaired OC maturation and bone resorption by suppressing the expression of TRAP and OC fusion proteins. In addition, p38 MAPK inhibitor also strongly inhibited OC formation and function. Our results suggest that the blockade of CD26 signaling impairs the development of human functional OCs by inhibiting p38 MAPK-mi/Mitf phosphorylation pathway and that targeting human OCs with huCD26mAb may have therapeutic potential for the treatment of osteolytic lesions following metastasis to alleviate bone destruction and reduce total skeletal-related events (SREs).

AB - Bone remodeling is maintained by the delicate balance between osteoblasts (OBs) and osteoclasts (OCs). However, the role of CD26 in regulating bone remodeling has not yet been characterized. We herein show that CD26 is preferentially expressed on normal human OCs and is intensely expressed on activated human OCs in osteolytic bone alterations. Macrophage-colony stimulating factor (M-CSF) and soluble receptor activator of NF-kB ligand (sRANKL) induced human OC differentiation, in association with CD26 expression on monocyte-macrophage lineage cells. CD26 expression was accompanied by increased phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK), which is crucial for early human OC differentiation. The humanized anti-CD26 monoclonal antibody, huCD26mAb, impaired the formation and function of tartrate-resistant acid phosphatase (TRAP)/CD26 positive multi-nucleated (nuclei>3) OCs with maturation in the manner of dose-dependency. It was revealed that huCD26mAb inhibits early OC differentiation via the inactivation of MKK3/6, p38 MAPK and subsequent dephosphorylation of microphthalmia-associated transcription factor (mi/Mitf). These inhibitions occur immediately after RANKL binds to RANK on the human OC precursor cells and were demonstrated using the OC functional assays. huCD26mAb subsequently impaired OC maturation and bone resorption by suppressing the expression of TRAP and OC fusion proteins. In addition, p38 MAPK inhibitor also strongly inhibited OC formation and function. Our results suggest that the blockade of CD26 signaling impairs the development of human functional OCs by inhibiting p38 MAPK-mi/Mitf phosphorylation pathway and that targeting human OCs with huCD26mAb may have therapeutic potential for the treatment of osteolytic lesions following metastasis to alleviate bone destruction and reduce total skeletal-related events (SREs).

KW - Bone resorption

KW - CD26

KW - Osteoclast

KW - Osteoclast precursor

KW - P38 mapk

UR - http://www.scopus.com/inward/record.url?scp=84923772941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923772941&partnerID=8YFLogxK

U2 - 10.1002/jbmr.2277

DO - 10.1002/jbmr.2277

M3 - Article

C2 - 24821427

AN - SCOPUS:84923772941

VL - 29

SP - 2439

EP - 2455

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - S1

ER -